Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

Autor: C. Fernández de Larrea, R. A. Kyle, B. G. M. Durie, H. Ludwig, S. Usmani, D. H. Vesole, R. Hajek, J. F. San Miguel, O. Sezer, P. Sonneveld, S. K. Kumar, A. Mahindra, R. Comenzo, A. Palumbo, A. Mazumber, K. C. Anderson, P. G. Richardson, A. Z. Badros, J. Caers, X. LeLeu, M. A. Dimopoulos, C. S. Chim, R. Schots, A. Noeul, D. Fantl, U. H. Mellqvist, O. Landgren, A. Chanan Khan, P. Moreau, R. Fonseca, G. Merlini, J. J. Lahuerta, J. Bladé, R. Z. Orlowski, J. J. Shah, on behalf of the International Myeloma Working Group [, CAVO, MICHELE, ZAMAGNI, ELENA
Přispěvatelé: C Fernández de Larrea, R A Kyle, B G M Durie, H Ludwig, S Usmani, D H Vesole, R Hajek, J F San Miguel, O Sezer, P Sonneveld, S K Kumar, A Mahindra, R Comenzo, A Palumbo, A Mazumber, K C Anderson, P G Richardson, A Z Badro, J Caer, M Cavo, X LeLeu, M A Dimopoulo, C S Chim, R Schot, A Noeul, D Fantl, U-H Mellqvist, O Landgren, A Chanan-Khan, P Moreau, R Fonseca, G Merlini, J J Lahuerta, J Bladé, R Z Orlowski, J J Shah, and on behalf of the International Myeloma Working Group [, Elena Zamagni, ], Hematology, Instituto de Salud Carlos III
Rok vydání: 2012
Předmět:
Zdroj: Leukemia, 27(4), 780-791. Nature Publishing Group
Fernández de Larrea, C, Kyle, R A, Durie, B G M, Ludwig, H, Usmani, S, Vesole, D H, Hajek, R, San Miguel, J F, Sezer, O, Sonneveld, P, Kumar, S K, Mahindra, A, Comenzo, R, Palumbo, A, Mazumber, A, Anderson, K C, Richardson, P G, Badros, A Z, Caers, J, Cavo, M, LeLeu, X, Dimopoulos, M A, Chim, C S, Schots, R, Noeul, A, Fantl, D, Mellqvist, U-H, Landgren, O, Chanan-Khan, A, Moreau, P, Fonseca, R, Merlini, G, Lahuerta, J J, Bladé, J, Orlowski, R Z, Shah, J J & International Myeloma Working Group 2013, ' Plasma cell leukemia : consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group ', Leukemia Insights, vol. 27, no. 4, pp. 780-91 . https://doi.org/10.1038/leu.2012.336
Digital.CSIC. Repositorio Institucional del CSIC
instname
ISSN: 1476-5551
0887-6924
Popis: PMCID: PMC4112539.-- International Myeloma Working Group: et al.
Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis or as secondary PCL in patients with relapsed/refractory myeloma. Primary PCL is a distinct clinic-pathological entity with different cytogenetic and molecular findings. The clinical course is aggressive with short remissions and survival duration. The diagnosis is based upon the percentage (≥20%) and absolute number (≥2 × 10 9/l) of plasma cells in the peripheral blood. It is proposed that the thresholds for diagnosis be re-examined and consensus recommendations are made for diagnosis, as well as, response and progression criteria. Induction therapy needs to begin promptly and have high clinical activity leading to rapid disease control in an effort to minimize the risk of early death. Intensive chemotherapy regimens and bortezomib-based regimens are recommended followed by high-dose therapy with autologous stem cell transplantation if feasible. Allogeneic transplantation can be considered in younger patients. Prospective multicenter studies are required to provide revised definitions and better understanding of the pathogenesis of PCL.
This work has been supported in part by “Josep Font” Grant from Hospital Clínic de Barcelona and RD06/0020/0005 from Instituto de Salud Carlos III, Spain.
Databáze: OpenAIRE
Externí odkaz: